Evolution of immunity to SARS-CoV-2
Authors:
- Adam K. WheatleyAdam K. Wheatley
- Jennifer A. JunoJJJennifer A. Juno
- Jing J. WangJWJing J. Wang
- Kevin J. SelvaKSKevin J. Selva
- Arnold ReynaldiARArnold Reynaldi
- Hyon-Xhi TanHTHyon-Xhi Tan
- Wen Shi LeeWLWen Shi Lee
- Kathleen M. WraggKWKathleen M. Wragg
- Hannah G. KellyHKHannah G. Kelly
- Robyn EsterbauerRERobyn Esterbauer
- Samantha K. DavisSDSamantha K. Davis
- Helen E. KentHKHelen E. Kent
Preprint
Abstract
The durability of infection-induced SARS-CoV-2 immunity has major implications for public health mitigation and vaccine development. Animal studies 1,2 and the scarcity of confirmed re-infection 3 suggests immune protection is likely, although the durability of this protection is debated. Lasting immunity following acute viral infection requires maintenance of both serum antibody and antigen-specific memory B and T lymphocytes and is notoriously pathogen specific, ranging from life-long for smallpox or measles 4 , to highly transient for common cold coronaviruses (CCC) 5 . Neutralising antibody responses are a likely correlate of protective immunity and exclusively recognise the viral spike (S) protein, predominantly targeting the receptor binding domain (RBD) within the S1 sub-domain 6 . Multiple reports describe waning of S-specific antibodies in the first 2-3 months following infection 7-12 . However, extrapolation of early linear trends in decay might be overly pessimistic, with several groups reporting that serum neutralisation is stable over time in a proportion of convalescent subjects 8,12-17 . While SARS-CoV-2 specific B and T cell responses are readily induced by infection 6,13,18-24 , the longitudinal dynamics of these key memory populations remains poorly resolved. Here we comprehensively profiled antibody, B and T cell dynamics over time in a cohort recovered from mild-moderate COVID-19. We find that binding and neutralising antibody responses, together with individual serum clonotypes, decay over the first 4 months post-infection, as expected, with a similar decline in S-specific CD4+ and circulating T follicular helper (cTFH) frequencies. In contrast, S-specific IgG+ memory B cells (MBC) consistently accumulate over time, eventually comprising a significant fraction of circulating MBC. Modelling of the concomitant immune kinetics predicts maintenance of serological neutralising activity above a titre of 1:40 in 50% of convalescent subjects to 74 days, with probable additive protection from B and T cells. Overall, our study suggests SARS-CoV-2 immunity after infection is likely to be transiently protective at a population level. SARS-CoV-2 vaccines may require greater immunogenicity and durability than natural infection to drive long-term protection.Keywords
All Related Versions
- Published version: Nature Communications, 12 (1), 1.
This publication has 37 references indexed in Scilit:
- Prolonged evolution of the memory B cell response induced by a replicating adenovirus-influenza H5 vaccineScience Immunology, 2019
- Precipitating anti-dsDNA peptide repertoires in lupusClinical and Experimental Immunology, 2018
- Low CD21 expression defines a population of recent germinal center graduates primed for plasma cell differentiationScience Immunology, 2017
- Prophylaxis With a Middle East Respiratory Syndrome Coronavirus (MERS-CoV)–Specific Human Monoclonal Antibody Protects Rabbits From MERS-CoV InfectionThe Journal of Infectious Diseases, 2016
- Correlates of protection to influenza virus, where do we go from here?Human Vaccines & Immunotherapeutics, 2013
- Fast Implementation for Normal Mixed Effects Models With Censored ResponseJournal of Computational and Graphical Statistics, 2009
- Duration of Humoral Immunity to Common Viral and Vaccine AntigensNew England Journal of Medicine, 2007
- CD4 T Cell-Mediated Protection from Lethal Influenza: Perforin and Antibody-Mediated Mechanisms Give a One-Two PunchThe Journal of Immunology, 2006
- Prior Infection and Passive Transfer of Neutralizing Antibody Prevent Replication of Severe Acute Respiratory Syndrome Coronavirus in the Respiratory Tract of MiceJournal of Virology, 2004
- Cutting Edge: Long-Term B Cell Memory in Humans after Smallpox VaccinationThe Journal of Immunology, 2003